Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Assets Average (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Assets Average readings, the most recent being $1.1 billion for Q4 2025.

  • For the quarter ending Q4 2025, Assets Average rose 19.42% year-over-year to $1.1 billion, compared with a TTM value of $1.1 billion through Dec 2025, up 19.42%, and an annual FY2025 reading of $980.2 million, up 17.12% over the prior year.
  • Assets Average hit $1.1 billion in Q4 2025 for Apellis Pharmaceuticals, up from $940.1 million in the prior quarter.
  • The five-year high for Assets Average was $1.1 billion in Q2 2022, with the low at $612.8 million in Q3 2021.
  • Median Assets Average over the past 5 years was $868.9 million (2023), compared with a mean of $871.4 million.
  • The sharpest move saw Assets Average fell 25.2% in 2021, then skyrocketed 53.02% in 2022.
  • Year by year, Assets Average stood at $703.7 million in 2021, then grew by 16.03% to $816.6 million in 2022, then fell by 1.6% to $803.5 million in 2023, then grew by 11.2% to $893.5 million in 2024, then rose by 19.42% to $1.1 billion in 2025.
  • According to Business Quant data, Assets Average over the past three periods came in at $1.1 billion, $940.1 million, and $814.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.